2024
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer.
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 10668969241256109. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with <i>TP53</i> mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53</i> mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival time
2017
Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer
Ogden A, Garlapati C, Li X, Turaga R, Oprea-Ilies G, Wright N, Bhattarai S, Mittal K, Wetherilt C, Krishnamurti U, Reid M, Jones M, Gupta M, Osan R, Pattni S, Riaz A, Klimov S, Rao A, Cantuaria G, Rida P, Aneja R. Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Scientific Reports 2017, 7: 42289. PMID: 28218233, PMCID: PMC5316996, DOI: 10.1038/srep42289.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalTNBC cellsOverall survivalPoor prognosisBreast cancerTriple-negative breast cancer patientsTriple-negative breast cancerMultivariable Cox modelMetastasis-free survivalWorse overall survivalBreast cancer patientsMulti-institutional studyAA TNBC patientsAfrican AmericansAfrican American womenTNBC patientsIndependent biomarkerPrognostic valueCancer patientsWorse outcomesCox modelTissue microarrayKIFC1 knockdownTNBCDistinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations
Wright N, Xia J, Cantuaria G, Klimov S, Jones M, Neema P, Il’yasova D, Krishnamurti U, Li X, Reid M, Gupta M, Rida P, Osan R, Aneja R. Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. PLOS ONE 2017, 12: e0170095. PMID: 28085947, PMCID: PMC5234824, DOI: 10.1371/journal.pone.0170095.Peer-Reviewed Original ResearchConceptsAdjuvant therapyNeoadjuvant chemotherapyRecurrence rateTumor recurrenceClinical studiesBreast cancer recurrence ratesBreast tumor recurrenceCohort of patientsBreast cancer patientsRate of recurrenceCancer recurrence rateAfrican American patientsFirst clinical studyHigh incidence rateEuropean American patientsForm of treatmentLocal recurrenceClinical outcomesPost therapyCancer patientsInvasive diseaseIncidence rateHigher overall rateRecurrence patternsHigh risk
2016
Chromosome 17 Aneuploidy Does Not Confer a Worse Prognosis in Breast Cancer Patients Younger Than 40 Years Old
Bousamra A, Annunziata J, Krishnamurti U, Silverman J. Chromosome 17 Aneuploidy Does Not Confer a Worse Prognosis in Breast Cancer Patients Younger Than 40 Years Old. American Journal Of Clinical Pathology 2016, 146: 218. DOI: 10.1093/ajcp/aqw156.009.Peer-Reviewed Original ResearchBiomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid M, O’Regan R, Aneja R. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal Of Clinical Pathology 2016, 145: 871-878. PMID: 27298399, DOI: 10.1093/ajcp/aqw045.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoadjuvant chemotherapyEstrogen receptorComplete responseLuminal subtypeProgesterone receptorBreast cancerTriple-negative breast cancer subtypeNottingham grade 3Stromal lymphocytic infiltrationNegative breast cancer subtypeBreast cancer patientsBreast cancer subtypesHigh mitotic countPR negativityHER2 positivityOverall cohortLymphocytic infiltrationTNBC subtypesCancer patientsHER2 statusPathologic parametersKi67 indexNuclear gradeClinical data